Multiple Myeloma Clinical Trials 2026: CAR-T, Bispecifics, and New Drugs
1,180 multiple myeloma trials indexed, 542 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Multiple Myeloma
Multiple myeloma is a type of blood cancer that begins in plasma cells, which are a kind of white blood cell found in bone marrow. These cells normally help fight infections by producing antibodies. In multiple myeloma, abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and producing harmful proteins. Doctors diagnose the disease using blood tests, bone marrow biopsies, and imaging scans. These tests check for abnormal protein levels, the number of plasma cells in bone marrow, and damage to bones or organs.
Common symptoms of multiple myeloma include bone pain, especially in the back or ribs, fatigue, frequent infections, and anemia. The disease is most often diagnosed in people over 65 years old, but it can occur earlier. Men are slightly more affected than women. Risk factors include a family history of the disease, exposure to radiation or certain chemicals, and having other plasma cell disorders. Early stages may have no symptoms, making diagnosis challenging without screening or routine blood work.
Multiple myeloma is medically significant because it affects the body’s ability to produce healthy blood cells and can cause serious complications like bone fractures and kidney damage. It accounts for about 1.8% of all new cancer cases in the United States annually. The five-year survival rate has improved but remains around 55%. Socially, the disease can cause long-term disability and requires ongoing treatment that impacts quality of life. The economic burden includes high costs for therapies and hospital care, making research into better treatments important.
The Multiple Myeloma Treatment Landscape
The first-line treatment for multiple myeloma usually involves a combination of therapies aimed at controlling the cancer and managing symptoms. This often includes drugs called immunomodulatory agents, proteasome inhibitors, and steroids. Patients may also receive stem cell transplants if they are eligible. Treatment is typically given in stages or lines, starting with the most effective options and moving to others if the disease progresses or side effects become too severe.
For patients whose disease returns or does not respond to first-line therapy, second- and third-line treatments are available. These include newer drug classes such as monoclonal antibodies and targeted therapies. Examples of established drugs include daratumumab, which targets a protein on myeloma cells, and carfilzomib, a proteasome inhibitor. Recently, therapies that use the immune system more directly, like CAR-T multiple myeloma treatments and bispecific antibodies, have been added to the options for relapsed or refractory cases.
Despite advances, there are still gaps in treatment. Some patients develop resistance to current drugs or experience severe side effects that limit their use. Certain subgroups, such as those with high-risk genetic features, tend to have poorer outcomes. Research is focusing on finding therapies that work earlier in the disease course and combining treatments to improve effectiveness. Trials are also testing new agents like BCMA CAR-T therapies (Carvykti, ciltacabtagene autoleucel; Abecma, idecabtagene vicleucel) and bispecific myeloma antibodies (Tecvayli, teclistamab; Elrexfio, elranatamab; Talvey, talquetamab) to address these issues.
Why Clinical Trials Matter for Multiple Myeloma
Clinical trials offer patients access to novel treatments that are not yet widely available. For multiple myeloma, there are currently about 1,180 clinical trials indexed on ClinicalTrials.gov, with 542 actively recruiting participants. These trials test new drugs, combinations, and treatment strategies to improve outcomes. Patients in trials often receive closer monitoring and contribute valuable information that helps advance science and future care options.
However, participating in clinical trials also involves risks. The effectiveness of new treatments is not guaranteed, and some trials include placebo groups or standard care comparison arms. Additional clinic visits and testing may be required, which can be time-consuming and tiring. Side effects from experimental therapies may also occur and are sometimes unpredictable. It is important for patients to weigh these factors carefully and discuss them with their healthcare team.
Multiple myeloma clinical trials are sponsored by a mix of academic institutions, pharmaceutical companies, and cooperative groups. These organizations work together to design and conduct studies that meet regulatory standards. ClinicalTrials.gov serves as a central registry where patients and caregivers can find detailed information about available trials. This transparency helps people identify studies that might fit their treatment needs and eligibility criteria, including trials for newly diagnosed patients or those with relapsed or refractory disease.
What to Look for in a Multiple Myeloma Clinical Trial
Clinical trials for multiple myeloma are divided into phases 1 through 4. Phase 1 trials focus on testing safety and dosage, usually with a small number of participants. Phase 2 trials look at how well the treatment works and continue to evaluate safety. Phase 3 trials compare the new treatment against the current standard of care in larger groups. Phase 4 trials occur after a treatment is approved to monitor long-term effects and effectiveness. For multiple myeloma, the distribution of trials is as follows: 161 trials have no phase specified, 130 are in phase 2, 108 in phase 1, and 61 in phase 3.
When considering eligibility for multiple myeloma clinical trials, there are common inclusion criteria. These often include age limits, typically adults 18 years or older, though some trials focus on older adults. Prior treatments are important: some trials accept only newly diagnosed patients, while others require patients to have relapsed or refractory disease after specific therapies. Biomarkers like BCMA expression or other genetic markers may be required. Disease staging and duration also matter, as some trials focus on early-stage disease while others target advanced or resistant cases.
Exclusion criteria help protect patient safety and ensure clear results. Patients with serious comorbidities such as uncontrolled heart or lung disease may be excluded. Drug interactions with current medications can also disqualify some patients. Safety thresholds like adequate blood counts and kidney function are common requirements. These criteria aim to reduce risks and avoid complications during the trial.
Practical considerations are important before joining a trial. Trial duration can range from several months to years depending on the study phase and treatment plan. Visit schedules may be frequent at first, requiring travel to the study center. Patients should ask the research team key questions: What are the possible side effects? How often will I need to visit the clinic? What happens if the treatment does not work? Are there costs or travel support available? These questions help patients and caregivers make informed decisions about participation.
Primary Sources and Further Reading
For patients and caregivers interested in learning more about multiple myeloma clinical trials and treatment options, it is helpful to consult trusted sources. These sites offer detailed, up-to-date information about the disease, ongoing studies, and guidance on clinical trial participation.
- National Cancer Institute: Multiple Myeloma
- ClinicalTrials.gov: Multiple Myeloma Clinical Trials
- MedlinePlus: Multiple Myeloma
- National Heart, Lung, and Blood Institute: Multiple Myeloma
Latest Research and Emerging Treatments for Multiple Myeloma (2026)
Recent multiple myeloma clinical trials have focused on therapies targeting BCMA and GPRC5D proteins found on myeloma cells. CAR-T multiple myeloma treatments like Carvykti (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel) use a patient’s own immune cells, which are modified in the lab to better recognize and attack cancer cells. These therapies are mostly studied in relapsed or refractory multiple myeloma, meaning patients whose disease has returned or not responded to prior treatments. Trials are now exploring if these BCMA CAR-T therapies can be used earlier in the treatment process to improve outcomes.
Bispecific myeloma antibodies such as Tecvayli (teclistamab), Elrexfio (elranatamab), and Talvey (talquetamab) are off-the-shelf treatments that work by connecting immune cells to myeloma cells, helping the immune system target the cancer more effectively. These bispecific antibodies are being tested in both newly diagnosed and relapsed multiple myeloma clinical trials. For example, a Phase 3 study is evaluating teclistamab alone or combined with lenalidomide as maintenance therapy after stem cell transplant in newly diagnosed patients (NCT05243797). These trials help define step-through-lines eligibility, meaning they test these new drugs at different stages of treatment depending on previous therapies.
New drugs for multiple myeloma in 2026 also include next-generation agents targeting GPRC5D, a protein found on myeloma cells. Trials are ongoing to see if these GPRC5D bispecifics can provide additional options for patients who have exhausted BCMA-targeted therapies. Overall, multiple myeloma research is advancing to offer more personalized treatment choices. For patients, this could mean more options with different side effect profiles and the possibility of longer disease control. These studies aim to improve quality of life and extend survival by testing new combinations and earlier use of promising therapies.
Frequently asked questions about Multiple Myeloma trials
How do I find Multiple Myeloma clinical trials?
The authoritative source for Multiple Myeloma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 1,180 multiple myeloma studies are currently indexed. You can search by entering "multiple myeloma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new multiple myeloma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Multiple Myeloma trials in?
Across the 1,180 multiple myeloma trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Multiple Myeloma clinical trials are currently recruiting?
As of the latest scan, 542 multiple myeloma trials have a "Recruiting" status on ClinicalTrials.gov, out of 1,180 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting multiple myeloma trial matches their tracked condition.
Stay informed about multiple myeloma research
Get a weekly briefing with the trials that matter most.